Frequency of infections during rituximab treatment of autoimmune blistering diseases

This study investigates the frequency of infections in autoimmune blistering disease (AIBD) patients treated with rituximab and evaluates the difference in infectious complications in patients on concomitant antibiotic and/or antiviral prophylaxis. The study retrospectively reviewed 43 AIBD patients who received rituximab over a five-year interval. The patients were categorized based on prophylaxis type (antibiotic, antiviral, or both) and concomitant immunosuppression status, which we defined as treatment with an immunosuppressive medication during the time frame they were given Rituximab. Our findings suggest that concomitant immunosuppression alongside rituximab did not significantly increase the risk of developing infectious complications compared to rituximab monotherapy. Results revealed that 34.4% of patients with concomitant immunosuppression had a secondary bacterial infection, defined as bacterial complications requiring hospitalization, consistent with prior studies. Moreover, antibiotic prophylaxis did not significantly reduce infection risk in patients on rituximab, with 45.1% of these patients experiencing bacterial complications. There was an absence of pneumocystis pneumonia in the study population. Despite the small sample size and limited timeline, this study suggests that antibiotic prophylaxis may not significantly mitigate the risk of infections in AIBD patients receiving rituximab, and the risk of infection with concomitant immunosuppression with rituximab requires additional investigation for definitive causal risk.

Gender distribution and NIH funding rank in dermatology leadership: a cross-sectional analysis

In examining the influence of National Institute of Health (NIH) funding on gender distribution within dermatology leadership roles, a cross-sectional analysis of Accreditation Council for Graduate Medical Education (ACGME) accredited dermatology residencies was conducted. The gender of leadership faculty was verified using online resources, while institutions were categorized by their 2022 NIH dermatology funding status. Results revealed that male dermatologists predominantly occupied department chair roles, whereas female dermatologists were more frequently found in associate program director roles, regardless of funding status. Notably, women held most program director positions in the top NIH-funded group, though this difference was not statistically significant due to a smaller sample size. The overall gender distribution has shown progress from 2021, with a significant rise in female associate program directors and a narrowing gender gap for chairs and program directors. Despite NIH funding rank playing a minimal role in gender distribution, our study underscores positive strides towards gender equality in dermatology leadership. Further advocacy for gender balance and additional research on underlying factors are essential for continued progress.